

Full Portfolio Holdings* as of June 30, 2026

The value of holdings represents the market value for non-derivative positions and unrealized appreciation/(depreciation) for derivative positions.

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
BASE CURRENCY					
US DOLLAR			18,001,890	18,001,890	2.31%
COMMON STOCKS					
Eli Lilly & Co.			80,883	97,013,497	12.44%
Johnson & Johnson			203,265	51,623,212	6.62%
Merck & Co., Inc.			399,431	51,326,884	6.58%
UnitedHealth Group, Inc.			88,244	36,676,854	4.70%
AbbVie, Inc.			106,556	26,813,752	3.44%
Intuitive Surgical, Inc.			58,611	23,308,422	2.99%
Elevance Health, Inc.			59,612	23,053,749	2.96%
CVS Health Corp.			220,811	22,842,898	2.93%
Vertex Pharmaceuticals, Inc.			42,701	21,210,868	2.72%
Danaher Corp.			109,308	20,820,988	2.67%
Edwards Lifesciences Corp.			209,097	18,914,915	2.42%
Abbott Laboratories			180,219	16,353,072	2.10%
Cencora, Inc.			57,130	16,166,647	2.07%
Cardinal Health, Inc.			59,512	14,137,671	1.81%
HCA Healthcare, Inc.			34,043	13,273,025	1.70%
Thermo Fisher Scientific, Inc.			25,552	12,810,751	1.64%
Regeneron Pharmaceuticals, Inc.			19,662	12,260,043	1.57%
Biogen, Inc.			51,492	11,125,362	1.43%
Agilent Technologies, Inc.			79,872	10,609,398	1.36%
GSK PLC			360,879	9,474,112	1.21%
Boston Scientific Corp.			217,321	9,275,260	1.19%
Stryker Corp.			29,293	9,222,608	1.18%
Centene Corp.			141,099	9,057,145	1.16%
Medtronic PLC			101,577	7,946,369	1.02%
United Therapeutics Corp.			13,777	7,464,792	0.96%
Incyte Corp.			64,367	7,296,643	0.94%
Dexcom, Inc.			102,748	6,920,078	0.89%
Argenx SE			7,064	6,553,767	0.84%
UCB SA			21,218	6,352,055	0.81%
Ionis Pharmaceuticals, Inc.			78,893	6,255,426	0.80%
STERIS PLC			29,188	6,146,117	0.79%
Alnylam Pharmaceuticals, Inc.			19,980	6,014,579	0.77%
Ascendis Pharma AS			22,341	5,958,792	0.76%
Madrigal Pharmaceuticals, Inc.			10,845	5,823,223	0.75%
Cytokinetics, Inc.			67,868	5,781,675	0.74%
PTC Therapeutics, Inc.			68,186	5,561,932	0.71%
Revolution Medicines, Inc.			29,017	5,434,304	0.70%
Elanco Animal Health, Inc.			215,158	5,295,038	0.68%
Bristol-Myers Squibb Co.			88,181	5,080,989	0.65%
Protagonist Therapeutics, Inc.			40,688	4,987,535	0.64%

Full Portfolio Holdings* as of June 30, 2026

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
Arcus Biosciences, Inc.			160,316	4,942,542	0.63%
AstraZeneca PLC			25,245	4,786,957	0.61%
Amgen, Inc.			13,004	4,709,008	0.60%
Galderma Group AG			20,401	4,640,155	0.59%
HeartFlow, Inc.			152,124	4,463,318	0.57%
Dianthus Therapeutics, Inc.			45,476	4,433,000	0.57%
Kymera Therapeutics, Inc.			38,652	4,432,225	0.57%
Pharvaris NV			123,487	4,270,180	0.55%
Bridgebio Pharma, Inc.			57,222	4,261,895	0.55%
Encompass Health Corp.			40,671	4,111,025	0.53%
Disc Medicine, Inc.			55,907	4,089,038	0.52%
ICON PLC			22,719	3,946,517	0.51%
Structure Therapeutics, Inc.			71,938	3,860,912	0.49%
Scholar Rock Holding Corp.			69,874	3,843,070	0.49%
Adaptive Biotechnologies Corp.			177,176	3,800,425	0.49%
Mirum Pharmaceuticals, Inc.			31,231	3,656,213	0.47%
Alignment Healthcare, Inc.			148,651	3,539,380	0.45%
Immunocore Holdings PLC			108,668	3,450,209	0.44%
Celldex Therapeutics, Inc.			92,052	3,425,255	0.44%
Option Care Health, Inc.			161,629	3,389,360	0.43%
Vaxcyte, Inc.			58,135	3,379,388	0.43%
Qiagen NV			84,169	3,291,008	0.42%
Kailera Therapeutics, Inc.			133,356	2,937,833	0.38%
CG oncology, Inc.			40,863	2,903,316	0.37%
Trevi Therapeutics, Inc.			155,503	2,900,131	0.37%
Acadia Healthcare Co., Inc.			92,071	2,718,857	0.35%
Stoke Therapeutics, Inc.			80,505	2,634,124	0.34%
Immunome, Inc.			118,955	2,520,656	0.32%
Jiangsu Hengrui Pharmaceuticals Co. Ltd.			317,981	2,352,642	0.30%
Definium Therapeutics, Inc.			49,500	2,328,480	0.30%
Inspire Medical Systems, Inc.			51,992	2,319,363	0.30%
GenFleet Therapeutics Shanghai, Inc.			583,800	2,206,189	0.28%
Crinetix Pharmaceuticals, Inc.			46,946	1,756,719	0.23%
Avalyn Pharma, Inc.			17,700	582,684	0.07%
Alebund Pharmaceuticals Jiangsu Ltd.			85,600	501,189	0.06%
Alamar Biosciences, Inc.			9,100	246,519	0.03%
Zenas Biopharma, Inc.			4,300	109,748	0.01%
FOREIGN CURRENCY					
BRAZILIAN REAL			1,906,284	369,270	0.05%
EURO CURRENCY			171	196	0.00%
DANISH KRONE			1,239	189	0.00%
HONG KONG DOLLAR			37	5	0.00%
JAPANESE YEN			1	0.01	0.00%
RIGHTS					
Abiomed, Inc.		12/31/2099	7,416	7,564	0.00%

Full Portfolio Holdings* as of June 30, 2026

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
SHORT-TERM INVESTMENTS					
Repurchase Agreement		7/1/2026	4,738,753	4,738,753	0.61%
TOTAL INVESTMENTS				783,101,845	100.38%
OTHER ASSETS LESS LIABILITIES				(2,957,505)	-0.38%
TOTAL NET ASSETS				780,144,339	100.00%

* This unaudited information is being presented pursuant to the Fund's Policy on Disclosure of Portfolio Holdings. Please see the Fund's Statement of Additional Information on www.hartfordfunds.com for a discussion of the Fund's policy. Holdings are provided for informational purposes only and should not be construed as a recommendation or investment advice. Portfolio holdings are as of the date noted and are subject to change at any time. Holdings may not be representative of current or future investments.

Unlike the Fund's regulatory filings, the portfolio data and its presentation in this document is not required to conform to Generally Accepted Accounting Principles (GAAP) and Securities and Exchange Commission (SEC) presentation requirements. Therefore, it may differ from that provided in the complete portfolio of investments in the annual and semiannual Financial Statements and Other Information filed with the SEC on Form N-CSR, and the complete portfolio of investments filed in the first and third quarter on Form N-PORT. In addition, the number of portfolio holdings listed above, which is sourced from the Fund's custodian, may differ from the "number of holdings" and related data points in the Fund Stats section of the webpage which is sourced from the sub-adviser.

Investing involves risk, including the possible loss of principal. Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in the fund's prospectus and summary prospectus, which can be obtained by visiting hartfordfunds.com. Please read it carefully before investing.

Mutual funds are distributed by Hartford Funds Distributors, LLC, Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC, an SEC registered investment adviser.

4673945 07/25